MedEquities Realty Trust (NYSE:MRT) was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Friday.

A number of other equities research analysts also recently issued reports on MRT. KeyCorp restated a “buy” rating and issued a $13.00 target price on shares of MedEquities Realty Trust in a report on Friday, August 25th. Cantor Fitzgerald started coverage on shares of MedEquities Realty Trust in a report on Thursday, August 31st. They issued an “overweight” rating and a $14.00 target price for the company. Capital One Financial started coverage on shares of MedEquities Realty Trust in a report on Monday, October 23rd. They issued an “equal weight” rating and a $13.00 target price for the company. B. Riley restated a “buy” rating on shares of MedEquities Realty Trust in a report on Wednesday, November 1st. Finally, Zacks Investment Research upgraded shares of MedEquities Realty Trust from a “sell” rating to a “hold” rating and set a $12.00 target price for the company in a report on Wednesday, November 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $12.83.

Shares of MedEquities Realty Trust (NYSE MRT) opened at $11.22 on Friday. MedEquities Realty Trust has a twelve month low of $10.06 and a twelve month high of $13.06. The stock has a market cap of $356.30, a P/E ratio of 10.20 and a beta of -0.75.

In other MedEquities Realty Trust news, CEO John W. Mcroberts purchased 18,000 shares of MedEquities Realty Trust stock in a transaction on Friday, November 17th. The shares were purchased at an average cost of $10.74 per share, with a total value of $193,320.00. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Randy L. Churchey purchased 5,300 shares of MedEquities Realty Trust stock in a transaction on Monday, November 20th. The shares were acquired at an average cost of $10.87 per share, for a total transaction of $57,611.00. Following the completion of the transaction, the director now owns 46,776 shares of the company’s stock, valued at $508,455.12. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 23,600 shares of company stock worth $254,129. 2.50% of the stock is currently owned by corporate insiders.

Hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. lifted its position in MedEquities Realty Trust by 10.8% during the first quarter. Vanguard Group Inc. now owns 1,095,341 shares of the financial services provider’s stock valued at $12,278,000 after buying an additional 106,394 shares in the last quarter. Prudential Financial Inc. lifted its position in MedEquities Realty Trust by 2.1% during the second quarter. Prudential Financial Inc. now owns 2,522,338 shares of the financial services provider’s stock valued at $31,832,000 after buying an additional 52,622 shares in the last quarter. American Century Companies Inc. lifted its position in MedEquities Realty Trust by 11.2% during the third quarter. American Century Companies Inc. now owns 1,726,208 shares of the financial services provider’s stock valued at $20,283,000 after buying an additional 174,261 shares in the last quarter. Northern Trust Corp lifted its position in MedEquities Realty Trust by 23.9% during the second quarter. Northern Trust Corp now owns 297,556 shares of the financial services provider’s stock valued at $3,755,000 after buying an additional 57,416 shares in the last quarter. Finally, Foundry Partners LLC lifted its position in MedEquities Realty Trust by 9.0% during the third quarter. Foundry Partners LLC now owns 526,740 shares of the financial services provider’s stock valued at $6,189,000 after buying an additional 43,350 shares in the last quarter. 93.19% of the stock is currently owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “MedEquities Realty Trust (MRT) Upgraded by ValuEngine to “Buy”” was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/03/medequities-realty-trust-mrt-upgraded-by-valuengine-to-buy.html.

About MedEquities Realty Trust

MedEquities Realty Trust, Inc is a real estate investment trust (REIT). The Company invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company invests primarily in real estate across the acute and post-acute spectrum of care. It focuses on investing in various types of healthcare properties, including acute care hospitals; skilled nursing facilities; short-stay surgical and specialty hospitals, which focus on orthopedic, heart and other dedicated surgeries and specialty procedures; dedicated specialty hospitals, such as inpatient rehabilitation facilities, long-term acute care hospitals and facilities providing psychiatric care; physician clinics; diagnostic facilities; outpatient surgery centers, and facilities that support these services, such as medical office buildings.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust Inc. and related companies with MarketBeat.com's FREE daily email newsletter.